JP2021535110A5 - - Google Patents

Info

Publication number
JP2021535110A5
JP2021535110A5 JP2021509758A JP2021509758A JP2021535110A5 JP 2021535110 A5 JP2021535110 A5 JP 2021535110A5 JP 2021509758 A JP2021509758 A JP 2021509758A JP 2021509758 A JP2021509758 A JP 2021509758A JP 2021535110 A5 JP2021535110 A5 JP 2021535110A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
alkyl
composition according
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509758A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590083B2 (ja
JP2021535110A (ja
Filing date
Publication date
Priority claimed from GBGB1814207.5A external-priority patent/GB201814207D0/en
Priority claimed from GBGB1908225.4A external-priority patent/GB201908225D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/073212 external-priority patent/WO2020043878A1/en
Publication of JP2021535110A publication Critical patent/JP2021535110A/ja
Publication of JP2021535110A5 publication Critical patent/JP2021535110A5/ja
Application granted granted Critical
Publication of JP7590083B2 publication Critical patent/JP7590083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509758A 2018-08-31 2019-08-30 併用療法 Active JP7590083B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1814207.5 2018-08-31
GBGB1814207.5A GB201814207D0 (en) 2018-08-31 2018-08-31 Combination Therapy
GB1908225.4 2019-06-10
GBGB1908225.4A GB201908225D0 (en) 2019-06-10 2019-06-10 Combination therapy
PCT/EP2019/073212 WO2020043878A1 (en) 2018-08-31 2019-08-30 Combination therapy

Publications (3)

Publication Number Publication Date
JP2021535110A JP2021535110A (ja) 2021-12-16
JP2021535110A5 true JP2021535110A5 (cg-RX-API-DMAC7.html) 2022-08-29
JP7590083B2 JP7590083B2 (ja) 2024-11-26

Family

ID=67841060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509758A Active JP7590083B2 (ja) 2018-08-31 2019-08-30 併用療法

Country Status (16)

Country Link
US (1) US20210322564A1 (cg-RX-API-DMAC7.html)
EP (1) EP3843748B1 (cg-RX-API-DMAC7.html)
JP (1) JP7590083B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210054520A (cg-RX-API-DMAC7.html)
CN (1) CN112638392B (cg-RX-API-DMAC7.html)
AU (1) AU2019332979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003675A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107085A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037206T3 (cg-RX-API-DMAC7.html)
IL (1) IL280968B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021001908A (cg-RX-API-DMAC7.html)
PH (1) PH12021550376A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101518QA (cg-RX-API-DMAC7.html)
UA (1) UA128954C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020043878A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100467B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202113092WA (en) * 2019-06-10 2021-12-30 Adc Therapeutics Sa Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
KR20240028449A (ko) * 2021-06-29 2024-03-05 에이디씨 테라퓨틱스 에스에이 항체-약물 접합체를 이용한 병용 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2906298T3 (en) * 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201506399D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2017160954A1 (en) * 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2018078123A1 (en) * 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
EP3612839A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy
KR102442736B1 (ko) * 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제

Similar Documents

Publication Publication Date Title
JP2022535609A5 (cg-RX-API-DMAC7.html)
JP2021524449A5 (cg-RX-API-DMAC7.html)
JP2022017295A5 (cg-RX-API-DMAC7.html)
JP5785157B2 (ja) Plk1阻害剤および抗腫瘍剤を含む治療組合せ
JP2024514339A5 (cg-RX-API-DMAC7.html)
JP2023036950A (ja) 癌治療のための組み合わせ療法
HRP20171727T1 (hr) Novi terapeutici
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
JP2020528880A5 (cg-RX-API-DMAC7.html)
JP2020505433A5 (cg-RX-API-DMAC7.html)
JP2017502993A5 (cg-RX-API-DMAC7.html)
FI3988117T3 (fi) Terapeuttiset vasta-aineet ja niiden käyttö
JP2019506403A5 (cg-RX-API-DMAC7.html)
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
JP2014510729A5 (cg-RX-API-DMAC7.html)
HRP20171758T1 (hr) Kombinacija dr5 agonista i anti-pd-1 antagonista i načini primjene
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2017502994A5 (cg-RX-API-DMAC7.html)
HRP20180945T1 (hr) Konjugati protutijelo-pirolobenzodiazepin
JP2022523740A5 (cg-RX-API-DMAC7.html)
JP2013518086A5 (cg-RX-API-DMAC7.html)
JP2021530444A5 (cg-RX-API-DMAC7.html)
JP2018525358A5 (cg-RX-API-DMAC7.html)
JP2021533090A5 (cg-RX-API-DMAC7.html)
JP2020531414A5 (cg-RX-API-DMAC7.html)